JP Morgan Chase
DTIL icon

JP Morgan Chase’s Precision BioSciences DTIL Stock Holding History

JP Morgan Chase’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Buy
180,452
+180,444
+2,255,550% +$1.27M ﹤0.01% 4428
2026
Q1 		$43 Hold
8
– – ﹤0.01% 7368
2025
Q4 		$33 Hold
8
– – ﹤0.01% 7273
2025
Q3 		$44 Hold
8
– – ﹤0.01% 7232
2025
Q2 		$34 Hold
8
– – ﹤0.01% 6923
2025
Q1 		$38 Hold
8
– – ﹤0.01% 7028
2024
Q4 		$30 Hold
8
– – ﹤0.01% 7211
2024
Q3 		$72 Hold
8
– – ﹤0.01% 7050
2024
Q2 		$78 Sell
8
-8,508
-100% -$100K ﹤0.01% 6937
2024
Q1 		$115K Buy
8,516
+422
+5% +$5.16K ﹤0.01% 5613
2023
Q4 		$88.6K Sell
8,094
-5,674
-41% -$61.2K ﹤0.01% 5791
2023
Q3 		$141K Sell
13,768
-55,782
-80% -$857K ﹤0.01% 5281
2023
Q2 		$1.1M Sell
69,550
-700
-1% -$16K ﹤0.01% 3992
2023
Q1 		$1.59M Buy
70,250
+17,257
+33% +$569K ﹤0.01% 3700
2022
Q4 		$1.89M Buy
52,993
+648
+1% +$25.6K ﹤0.01% 3600
2022
Q3 		$2.04M Buy
52,345
+22,124
+73% +$1.05M ﹤0.01% 3443
2022
Q2 		$1.45M Buy
30,221
+9
+0% +$528 ﹤0.01% 3816
2022
Q1 		$2.79M Buy
30,212
+5,494
+22% +$746K ﹤0.01% 3488
2021
Q4 		$5.49M Sell
24,718
-5,275
-18% -$1.47M ﹤0.01% 2974
2021
Q3 		$10.4M Buy
29,993
+12,801
+74% +$4.34M ﹤0.01% 2354
2021
Q2 		$6.46M Buy
17,192
+10,436
+154% +$3.13M ﹤0.01% 2826
2021
Q1 		$2.1M Buy
6,756
+2,201
+48% +$771K ﹤0.01% 3697
2020
Q4 		$1.14M Buy
4,555
+1,201
+36% +$294K ﹤0.01% 3867
2020
Q3 		$641K Buy
3,354
+511
+18% +$102K ﹤0.01% 3873
2020
Q2 		$710K Sell
2,843
-5,159
-64% -$1.13M ﹤0.01% 3695
2020
Q1 		$1.45M Buy
8,002
+4,872
+156% +$1.28M ﹤0.01% 3182
2019
Q4 		$1.3M Buy
3,130
+3,030
+3,030% +$952K ﹤0.01% 3672
2019
Q3 		$25K Buy
100
+16
+19% +$5.21K ﹤0.01% 5354
2019
Q2 		$33K Sell
84
-1,249
-94% -$503K ﹤0.01% 5322
2019
Q1 		$718K Buy
+1,333
New +$708K ﹤0.01% 3996

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

JP Morgan Chase's DTIL Position: Q2 2026 in Review

JP Morgan Chase increased its Precision BioSciences (DTIL) stake by 2,255,550% in Q2 2026, buying an estimated $1.27M and bringing the position to 180,452 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #4428.

JP Morgan Chase first reported a position in DTIL in Q1 2019 and has held it in 30 quarters since. The position peaked at $10.4M in Q3 2021. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • JP Morgan Chase held 180,452 shares of Precision BioSciences worth $1.43M as of Q2 2026.
  • JP Morgan Chase bought 180,444 Precision BioSciences shares in Q2 2026, an estimated $1.27M.
  • Precision BioSciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4428 holding.
  • JP Morgan Chase first reported a position in Precision BioSciences in Q1 2019 and has held it in 30 quarters since.
  • JP Morgan Chase's Precision BioSciences position peaked at $10.4M in Q3 2021.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.